EP3110942A4 - Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu - Google Patents

Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu Download PDF

Info

Publication number: EP3110942A4
Authority: EP; European Patent Office
Prior art keywords: her2; compositions; treatment; methods; expressing tumors
Prior art date: 2014-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP15755609.3A

Other languages

German (de)

English (en)

Other versions

EP3110942A2 (fr

Inventor

Vafa Shahabi

Anu Wallecha

Paulo C. Maciag

Yvonne Paterson

Nicola Mason

Matthew Seavey

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Pennsylvania Penn

Ayala Pharmaceuticals Inc

Original Assignee

University of Pennsylvania Penn

Advaxis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-02-25

Filing date

2015-02-25

Publication date

2017-08-30

2014-02-25 Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en

2014-05-02 Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en

2015-02-25 Application filed by University of Pennsylvania Penn, Advaxis Inc filed Critical University of Pennsylvania Penn

2017-01-04 Publication of EP3110942A2 publication Critical patent/EP3110942A2/fr

2017-08-30 Publication of EP3110942A4 publication Critical patent/EP3110942A4/fr

Status Withdrawn legal-status Critical Current

Links

101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP15755609.3A 2014-02-25 2015-02-25 Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu Withdrawn EP3110942A4 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US14/189,008 US20150366955A9 (en)	2009-11-11	2014-02-25	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en)	2009-11-11	2014-05-02	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P	2014-11-06	2014-11-06
PCT/US2015/017559 WO2015130810A2 (fr)	2014-02-25	2015-02-25	Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu

Publications (2)

Publication Number	Publication Date
EP3110942A2 EP3110942A2 (fr)	2017-01-04
EP3110942A4 true EP3110942A4 (fr)	2017-08-30

Family

ID=54009773

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP15755609.3A Withdrawn EP3110942A4 (fr)	2014-02-25	2015-02-25	Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu

Country Status (12)

Country	Link
EP (1)	EP3110942A4 (fr)
JP (1)	JP2017507943A (fr)
KR (2)	KR20240038103A (fr)
CN (1)	CN106661538A (fr)
AU (1)	AU2015223136A1 (fr)
BR (1)	BR112016019534A2 (fr)
CA (1)	CA2940646A1 (fr)
IL (1)	IL247436A0 (fr)
MX (1)	MX2016011114A (fr)
RU (1)	RU2016137834A (fr)
SG (1)	SG11201607036XA (fr)
WO (1)	WO2015130810A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9012141B2 (en)	2000-03-27	2015-04-21	Advaxis, Inc.	Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (fr)	2011-03-11	2012-09-20	John Rothman	Adjuvants a base de listeria
WO2013138337A1 (fr)	2012-03-12	2013-09-19	Advaxis	Inhibition de la fonction des cellules suppresseurs après traitement par un vaccin à base de listeria
JP2017511796A (ja)	2014-02-18	2017-04-27	アドバクシス，インコーポレイテッド	多標的免疫療法を目的とするバイオマーカー
AU2015227163A1 (en) *	2014-03-05	2016-10-20	Advaxis, Inc.	Methods and compositions for increasing a T-effector cell to regulatory T cell ratio
EP3134510B1 (fr)	2014-04-24	2023-11-01	Advaxis, Inc.	Souches de listeria utilisées comme vaccin recombinant et procédé de production
MA41644A (fr)	2015-03-03	2018-01-09	Advaxis Inc	Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
ES2970865T3 (es)	2015-12-16	2024-05-31	Gritstone Bio Inc	Identificación, fabricación y uso de neoantígenos
CA3035591A1 (fr)	2016-11-30	2018-06-07	Advaxis, Inc.	Compositions immunogenes ciblant des mutations recurrentes du cancer et leurs procedes d'utilisation
AU2018336988B2 (en)	2017-09-19	2023-06-22	Advaxis, Inc.	Compositions and methods for lyophilization of bacteria or Listeria strains
EP4576103A3 (fr)	2017-10-10	2025-08-27	Gritstone bio, Inc.	Identification de néoantigènes à l'aide de points chauds
CN111630602A (zh)	2017-11-22	2020-09-04	磨石肿瘤生物技术公司	减少新抗原的接合表位呈递

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120014984A1 (en) *	2009-11-11	2012-01-19	Vafa Shahabi	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6855320B2 (en) *	2000-03-29	2005-02-15	The Trustees Of The University Of Pennsylvania	Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity

2015
- 2015-02-25 EP EP15755609.3A patent/EP3110942A4/fr not_active Withdrawn
- 2015-02-25 CA CA2940646A patent/CA2940646A1/fr active Pending
- 2015-02-25 RU RU2016137834A patent/RU2016137834A/ru not_active Application Discontinuation
- 2015-02-25 MX MX2016011114A patent/MX2016011114A/es unknown
- 2015-02-25 BR BR112016019534A patent/BR112016019534A2/pt not_active Application Discontinuation
- 2015-02-25 KR KR1020247007406A patent/KR20240038103A/ko active Pending
- 2015-02-25 KR KR1020167025517A patent/KR20160122829A/ko not_active Ceased
- 2015-02-25 WO PCT/US2015/017559 patent/WO2015130810A2/fr not_active Ceased
- 2015-02-25 AU AU2015223136A patent/AU2015223136A1/en not_active Abandoned
- 2015-02-25 SG SG11201607036XA patent/SG11201607036XA/en unknown
- 2015-02-25 CN CN201580010568.4A patent/CN106661538A/zh active Pending
- 2015-02-25 JP JP2016553897A patent/JP2017507943A/ja active Pending
2016
- 2016-08-23 IL IL247436A patent/IL247436A0/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20120014984A1 (en) *	2009-11-11	2012-01-19	Vafa Shahabi	Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Also Published As

Publication number	Publication date
WO2015130810A2 (fr)	2015-09-03
IL247436A0 (en)	2016-11-30
MX2016011114A (es)	2017-02-20
BR112016019534A2 (pt)	2017-10-24
KR20160122829A (ko)	2016-10-24
NZ723750A (en)	2024-02-23
CA2940646A1 (fr)	2015-09-03
EP3110942A2 (fr)	2017-01-04
AU2015223136A1 (en)	2016-09-22
KR20240038103A (ko)	2024-03-22
RU2016137834A (ru)	2018-03-29
CN106661538A (zh)	2017-05-10
SG11201607036XA (en)	2016-09-29
WO2015130810A3 (fr)	2016-01-28
JP2017507943A (ja)	2017-03-23

Legal Events

Date	Code	Title	Description
2016-12-02	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2016-12-02	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-01-04	17P	Request for examination filed	Effective date: 20160916
2017-01-04	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-01-04	AX	Request for extension of the european patent	Extension state: BA ME
2017-08-30	A4	Supplementary search report drawn up and despatched	Effective date: 20170801
2017-08-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101ALI20170726BHEP Ipc: C12N 1/20 20060101ALI20170726BHEP Ipc: C12N 1/12 20060101AFI20170726BHEP
2018-01-12	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1232563 Country of ref document: HK
2019-01-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2019-02-20	17Q	First examination report despatched	Effective date: 20190117
2019-10-04	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-11-06	18D	Application deemed to be withdrawn	Effective date: 20190528
2023-09-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1232563 Country of ref document: HK

Publication	Publication Date	Title
HUS2500001I1 (hu)	2025-01-28	Antitestkészítmények daganatkezelésre
EP3092254A4 (fr)	2017-09-20	Composés et compositions pour traiter des tumeurs à her2 positif
EP3110942A4 (fr)	2017-08-30	Compositions et méthodes pour le traitement de tumeurs à surexpression de her2/neu
ZA201802831B (en)	2021-07-28	Composition for the treatment of igf-1r expressing cancer
EP3399982A4 (fr)	2019-09-18	Associations anti-egfr pour le traitement de tumeurs
EP3166640A4 (fr)	2018-06-13	Compositions de thérapie combinatoire et méthodes de traitement de cancers
EP3209382A4 (fr)	2018-06-20	Technique d'immunotherapie combinee pour le traitement du cancer
EP3148532A4 (fr)	2018-01-03	Association pharmaceutique pour le traitement du cancer
EP3134436A4 (fr)	2017-12-27	Traitement de tumeurs provoquées par h-ras
EP3110443A4 (fr)	2017-11-15	Thérapie combinée pour le traitement du cancer
EP3200815A4 (fr)	2018-04-25	Procédés et compositions pour le traitement du cancer
EP3104880A4 (fr)	2017-10-18	Procédés améliorés pour le traitement de cancers liés à la vascularisation
EP3227686A4 (fr)	2018-08-29	Analyses d'immunocytochimie multiplexées pour le diagnostic et le traitement d'un cancer
EP3089992A4 (fr)	2017-07-19	Compositions et méthodes pour l'imagerie du cancer
EP3177308A4 (fr)	2018-04-04	Utilisation de peptides qui bloquent l'interaction métadhérine-snd1 pour le traitement du cancer
EP3139919A4 (fr)	2018-01-10	Composés destinés au traitement du cancer
EP3185910A4 (fr)	2018-01-10	Méthodes et compositions pour le traitement du cancer
EP3548007A4 (fr)	2020-08-12	Méthodes de traitement du cancer
EP3154952A4 (fr)	2018-03-14	Méthodes et compositions pour traiter les cancers her positifs
EP3180011A4 (fr)	2018-03-21	Immunothérapie pour le traitement du cancer
EP3169333A4 (fr)	2018-03-07	Méthodes et compositions pour améliorer un traitement anticancéreux
EP3285763A4 (fr)	2018-12-05	Compositions pour le traitement du cancer
EP3160591A4 (fr)	2018-04-04	Compositions et méthodes pour le traitement du cancer
HK40007662A (en)	2020-06-05	Methods and compositions for cancer therapy
HK1260504A1 (en)	2019-12-20	Compositions and methods for treatment of cancer